Nutraceutix issued Australian patent
In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according
Full Post: First-degree family history of prostate cancer does not affect some treatment outcomes
The Australian Patent Office has issued Nutraceutix, Inc. a patent for BIO-tract.
It is the third international patent, from many patents pending, that the technology has been awarded based on BIO-tract’s ability to protect sensitive ingredients like probiotic organisms from stomach acid on their way to optimal release sites in the intestinal tract.
Steve Moger, President and CEO of Nutraceutix comments: “Many years ago, we recognized the need for an effective probiotic and nutraceutical delivery technology — one that draws from proven pharmaceutical principals, but does so in a fashion that is economically feasible in the nutritional supplement marketplace. With BIO-tract, we have addressed this need.”
In the case of probiotics, three critical barriers must be overcome to fully benefit the consumer.
- Survival of these beneficial, but fragile organisms through the manufacturing process
- Survival on the store shelf
- Safe passage through the harsh stomach acids that may denature the organisms
BIO-tract products incorporate proven processes and technologies to overcome these barriers.
How BIO-tract works
Once ingested, BIO-tract tablets form a protective layer, which shields probiotic organisms from the acidic conditions of the stomach. After passing from the stomach to the intestinal tract, the tablets release the organisms at optimal rates determined by formulation.
Broad applications for BIO-tract
Application of the BIO-tract delivery system is not limited to probiotics. It has been applied to many other ingredients that benefit from effective gastric acid protection, buffering, controlled release and once-daily dosing. Custom BIO-tract formulations allow the controlled release of active ingredients at rates ranging from just a few hours to all day long.
According to a recent study from the University and the University Central Hospital of Helsinki, Finland, no allergy-preventive effect is extended to age 5 years by perinatal supplementation with probiotics in babies at risk for developing allergies; protection is conferred only to Cesarean section babies. Childhood allergies have increased significantly in industrialized countries during the
Full Post: Probiotics prevent IgE-associated allergy until age 5 in cesarean-delivered children but not in total cohort
Prilosec is one of the best anti acid drugs that has been approved by the FDA as the best treatment for gastroesophageal reflux disease and gastric ulcers. According to the health professionals, a lot of acid in the stomach may lead to acid reflux. Prilosec performs its duties by blocking the enzymes that stimulate the
Full Post: Prilosec is one of the best anti acid drug
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets. As part of the settlements, the
Full Post: Barr announces agreements on Nasacort AQ, Allegra D-12 and Allegra patent challenges
Contrary to a widely-held assumption about heterosexual transmission of HIV, the normal mucosal lining of the female genital tract is not a foolproof barrier to viral penetration, scientists at the Northwestern University School of Medicine in Chicago report at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.
Full Post: Mucosal lining of the female genital tract no barrier to HIV sexual transmission
Mylan Inc. has announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Novartis Pharmaceuticals Corp., Novartis Corp. and Novartis International AG related to Letrozole Tablets, the generic version of Novartis’ Femara. Mylan’s Vice Chairman and CEO Robert J. Coury commented: “We are very pleased to have reached this
Full Post: Mylan settles with Novartis on Femara